BrightGene Bio-Medical Technology Co., Ltd.
Cena
Kam míří tržby
Načítám tok výsledovky…
Odkud plynou tržby
Fundamenty
Načítám klíčová čísla…
Insideři, analytici a lidé
Všechny obchody a změnyNačítám insidery, analytiky a názory…
Co se právě děje
AI souhrnO společnosti
BrightGene Bio-Medical Technology Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products in China and internationally. The company develops BGM0504 injection, which is in Phase III clinical trial for treatment of type 2 diabetes and weight loss; and BGM1812, a long-acting amylin analog in preclinical development. It also provides formulations; active pharmaceutical ingredients and intermediates; and veterinary drugs for various therapeutic areas, including metabolism, respiratory, immunosuppression, antiviral, antifungal, antitumor, cerebrovascular, iron supplement, antibodies drug conjugate, anti-infection, imaging, intermediates, gynecology, cardiovascular, digestion, and others. In addition, the company is involved in technology research and development; import, export, wholesale, and retail of medicines; production and operation of medical devices; medical research and experimental development; and technical services. BrightGene Bio-Medical Technology Co., Ltd. was founded in 2001 and is based in Suzhou, China.
Český popis připravujeme.
- Zaměstnanci
- 1 196
- Země
- Čína
- Data od
- 8. 11. 2019